Early Effectiveness of Bedaquiline Containing Regimen in Treatment of Multidrug-resistant and Extensively Drug-resistant Pulmonary Tuberculosis: An One-arm Observational Study of 24 Weeks

Chunhong YU; Yanhong ZHAO; Xing LIU; Lingjun SHEN; Weixian LI; Haiwen LI; Hao FAN

doi:10.12259/j.issn.2095-610X.S20221113

Volume 43 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(11): 99-106

Chunhong YU, Yanhong ZHAO, Xing LIU, Lingjun SHEN, Weixian LI, Haiwen LI, Hao FAN. Early Effectiveness of Bedaquiline Containing Regimen in Treatment of Multidrug-resistant and Extensively Drug-resistant Pulmonary Tuberculosis: An One-arm Observational Study of 24 Weeks[J]. Journal of Kunming Medical University, 2022, 43(11): 99-106. doi: 10.12259/j.issn.2095-610X.S20221113

Citation:

Chunhong YU, Yanhong ZHAO, Xing LIU, Lingjun SHEN, Weixian LI, Haiwen LI, Hao FAN. Early Effectiveness of Bedaquiline Containing Regimen in Treatment of Multidrug-resistant and Extensively Drug-resistant Pulmonary Tuberculosis: An One-arm Observational Study of 24 Weeks[J]. Journal of Kunming Medical University, 2022, 43(11): 99-106. doi: 10.12259/j.issn.2095-610X.S20221113

Citation:

Chunhong YU, Yanhong ZHAO, Xing LIU, Lingjun SHEN, Weixian LI, Haiwen LI, Hao FAN. Early Effectiveness of Bedaquiline Containing Regimen in Treatment of Multidrug-resistant and Extensively Drug-resistant Pulmonary Tuberculosis: An One-arm Observational Study of 24 Weeks[J]. Journal of Kunming Medical University, 2022, 43(11): 99-106. doi: 10.12259/j.issn.2095-610X.S20221113

PDF( 702 KB)

Early Effectiveness of Bedaquiline Containing Regimen in Treatment of Multidrug-resistant and Extensively Drug-resistant Pulmonary Tuberculosis: An One-arm Observational Study of 24 Weeks

doi: 10.12259/j.issn.2095-610X.S20221113

1.
School of Pharmacy，Dali University，Dali Yunnan 671000
2.
Dept. of Pharmacy，Kunming Third People’s Hospital /Yunnan Clinical Center for Infectious Disease， Kunming Yunnan 650041，China

Received Date: 2022-07-14
Publish Date: 2022-11-25

Abstract

Abstract

Objective To evaluate the efficacy of a bedaquiline-containing regimen in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis, and to explore the adverse reactions, so as to provide a reference for safe and rational drug use in clinical practice. Methods The clinical data of 62 patients with multi-drug resistant/extensively drug-resistant tuberculosis treated with a bedaquiline-containing regimen from October 2019 to October 2021 in the Third People’s Hospital of Kunming were retrospectively analyzed to evaluate the efficacy and safety of bedaquiline-containing regimen. Background Drug composition, number and days of sputum negative conversion, lesion absorption, cavity closure, and distribution of adverse events were counted, and their correlation was analyzed. QTcF values （corrected for heart rate, QT interval values calculated using the Fridericia formula） were recorded before and after medication, and changes from baseline at each monitoring point were compared and analyzed. Results All 62 patients were followed up for 24 weeks, and there were no deaths, lost to follow-up or withdrawal cases; At the end of 24 weeks of treatment, the sputum smear-negative conversion rate was 93.5% （58/62）, the sputum culture negative conversion rate was 85.4% （53/62）, the lesion absorption rate was 87.1% （54/62）, and the cavity closure rate was 92.3% （36/39） in 39 patients with cavities. There were a total of 217 adverse events, 203 （93.5%） were mild to moderate （grade 1 to 2） adverse events and 14 （6.5%） were serious （grade 3 to 5） adverse events. A total of 22 discontinuations were performed during treatment. Bedaquiline-related adverse events were 11 discontinuations, mainly manifested as QTc prolongation in 9 （41.0%） and hepatotoxicity in 2 （9.1%）. Statistical calculation results showed that abnormal liver function was negatively correlated with sputum negative conversion time （z = -0.293, P < 0.01）; QTc interval prolongation was negatively correlated with sputum negative conversion time （ z = -0.544, P < 0.01）. Sixty-two patients were compared between the mean QTcF value at each monitoring site and the baseline QTcF value, and the QTcF value gradually increased with the extension of the course of treatment, and the differences at weeks 4, 8, 12, 16, and 24 were statistically significant. Conclusions Bedaquiline-containing regimens achieve a high rate of sputum negative conversion at 24 weeks in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis and can promote the absorption of imaging lesions in patients. Although the incidence of adverse drug reactions is high, they are generally controllable and tolerable to most patients. Special attention should be paid to QTc prolongation and liver injury during medication.
- Bedaquiline,
- Tuberculosis,
- Multidrug-resistant pulmonary tuberculosis,
- Extensively drug-resistant tuberculosis,
- Retrospective study

FullText(HTML)

References(26)

References

[1]	卢春容,房宏霞,陆普选,等. WHO 2021年全球结核病报告:全球与中国关键数据分析[J]. 新发传染病电子杂志,2021,6(04):368-372.
[2]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment[M]. Geneva: World Health Organization, 2020: 19-21.
[3]	周文强,初乃惠. 耐药结核病治疗的进展[J]. 中国临床医生杂志,2020,48(12):1396-1399. doi: 10.3969/j.issn.2095-8552.2020.12.004
[4]	李仁忠,阮云洲,李玉红. 关于世界卫生组织广泛耐药结核病新定义的解读[J]. 中国防痨杂志,2021,43(06):539-541. doi: 10.3969/j.issn.1000-6621.2021.06.003
[5]	Andries K,Verhasselt P,Guillemont J,et al. A diarylquinoline drug active on the ATPsynthase of Mycobacterium tuberculosis[J]. Science,2005,307(5707):223-227. doi: 10.1126/science.1106753
[6]	Huitric E,Verhasselt P,Andries K,et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor[J]. Antimicrob Agents Chemother,2007,51(11):4202-4204. doi: 10.1128/AAC.00181-07
[7]	Diacon A H,Pym A,Grobusch M,et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis[J]. N Engl J Med,2009,360(23):2397-2405. doi: 10.1056/NEJMoa0808427
[8]	Diacon A H,Donald P R,Pym A,et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis:long-term outcome,tolerability,and effect on emergence of drug resistance[J]. Antimicrob Agents Chemother,2012,56(6):3271-3276. doi: 10.1128/AAC.06126-11
[9]	Diacon A H,Pym A,Grobusch M P,et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline[J]. N Engl J Med,2014,371(8):723-732. doi: 10.1056/NEJMoa1313865
[10]	中国防痨协会. 耐药结核病治疗指南（2019简版）[S]. 中国防痨杂志, 2019, 41（10）: 1025-1073.
[11]	U. S. Department of Health and Human Services. Common terminology criteria for adverse events（CTCAE）[EB/OL]. （2017-11-27）[2021-01-21]. https://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
[12]	Gao J T,Du J,Wu G H,et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China:focus on the safety[J]. Infect Dis Poverty,2021,10(1):32-40. doi: 10.1186/s40249-021-00819-2
[13]	杨梁梓,任坦坦,傅向东,等. 含贝达喹啉新方案治疗耐药肺结核的疗效与安全性研究[J]. 新发传染病电子杂志,2021,6(4):302-305.
[14]	田丹,胡晓萌,金武,等. 含贝达喹啉方案治疗67例痰菌培养转阴的耐多药/广泛耐药肺结核患者单臂单中心临床观察[J]. 中国防痨杂志,2021,43(11):1146-1152. doi: 10.3969/j.issn.1000-6621.2021.11.008
[15]	中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识（2020年更新版）[S]. 中华结核和呼吸杂志, 2021, 44（2）: 81-87.
[16]	凌慧琪,陈伟杰,何显科. 富马酸贝达喹啉片治疗耐多药肺结核的临床疗效分析[J]. 广西医科大学学报,2021,38(7):1442-1447.
[17]	任娜,胡善雷,刘金瑾,等. 富马酸贝达喹啉片治疗耐多药肺结核的疗效观察[J]. 临床肺科杂志,2021,26(7):1047-1051. doi: 10.3969/j.issn.1009-6663.2021.07.018
[18]	程凯,李娜,陈效友,等. 84例利奈唑胺导致耐药结核病患者的不良反应分析[J]. 中国医院用药评价与分析,2022,22(3):374-377. doi: 10.14009/j.issn.1672-2124.2022.03.026
[19]	邹莉萍,时正雨,梁丽,等. 含贝达喹啉及利奈唑胺方案治疗耐多药结核病24周疗效及安全性观察[J]. 临床肺科杂志,2022,27(3):415-421. doi: 10.3969/j.issn.1009-6663.2022.03.018
[20]	Pym A S,Diacon A H,Tang S J,et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis[J]. Eur Respir J,2016,47(2):564-574. doi: 10.1183/13993003.00724-2015
[21]	时正雨,吴桂辉,黄涛,等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的24周单组观察性研究[J]. 中国防痨杂志,2021,43(5):487-494. doi: 10.3969/j.issn.1000-6621.2021.05.014
[22]	陈艳,安琪,林瑞,等. 77例耐多药肺结核患者采用含贝达喹啉方案治疗后肝损伤和QTc延长的临床分析[J]. 临床肺科杂志,2021,26(12):1886-1891. doi: 10.3969/j.issn.1009-6663.2021.12.022
[23]	裴异,高静韬,黄云辉,等. 含贝达喹啉方案治疗44例痰菌阳性耐多药/广泛耐药肺结核24周疗效分析[J]. 中国防痨杂志,2021,43(11):1139-1145. doi: 10.3969/j.issn.1000-6621.2021.11.007
[24]	Ahmad N,Ahuja S D,Akkerman O W,et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis:an individual patient data meta-analysis[J]. Lancet,2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1
[25]	谢莉,朱慧,高静韬,等. 贝达喹啉血药浓度在耐药肺结核治疗中的变化及其与QTc间期延长的相关性[J]. 中国防痨杂志,2022,44(3):219-226. doi: 10.19982/j.issn.1000-6621.20210696
[26]	Pontali E,Sotgiu G,Tiberi S,et al. Cardiac safety of bedaquiline:a systematic and critical analysis of the evidence[J]. Eur Respir J,2017,50(5):1701462.

Relative Articles(20)

Relative Articles

[1]	Xiaoyan WANG, Ya LI, Chenglu HE, Lin WANG, Zhiqiang MA, Xinrui WAN. Study on Immune Function and Drug Resistance of Tuberculosis Patients Co-infected with HBV，HCV and HIV in Yunnan. Journal of Kunming Medical University, 2023, 44(12): 51-58. doi: 10.12259/j.issn.2095-610X.S20231209
[2]	Xiaoli WANG, Hongwei YANG, Ting DING, Ruiping WU, Kuixuan ZHU. The Clinical Data Analysis of 2 499 Patients with Nasopharyngeal Carcinoma in Yunnan. Journal of Kunming Medical University, 2023, 44(5): 154-161. doi: 10.12259/j.issn.2095-610X.S20230523
[3]	Xing LIU, Chunhong YU, Weixian LI, Bing OUYANG, Lingjun SHEN. A Randomized Controlled Study on the Treatment of Multidrugresistant Tuberculosis with a Regimen Containing Bedaquiline Fumarate Tablets. Journal of Kunming Medical University, 2023, 44(12): 150-158. doi: 10.12259/j.issn.2095-610X.S20231224
[4]	Rong WAN, Guangmei LI, Meng MA, Minghong LAI, Cai LIU, Mingwu LI. Clinical Features of Tuberculosis with Negative T Cell Spot Test in Peripheral Blood. Journal of Kunming Medical University, 2022, 43(4): 132-136. doi: 10.12259/j.issn.2095-610X.S20220420
[5]	Sixue PAN, Chaoyu BAO, Jiliang XIA, Guangxiong HE, Yu LU, Junyi XIANG. A Retrospective Study of 64-row 128-slice Spiral CT Digital Imaging Data of Normal Adult Coracoid Process. Journal of Kunming Medical University, 2022, 43(10): 84-89. doi: 10.12259/j.issn.2095-610X.S20221017
[6]	Zhao XIANG, Jin-hui YANG. Clinical Efficacy of Non-biological Artificial Liver in 112 Patients with Liver Failure. Journal of Kunming Medical University, 2021, 42(12): 140-144. doi: 10.12259/j.issn.2095-610X.S20211034
[7]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[8]	Xing LIU, Bing OUYANG, Na LI, Ji LUO, Xu-qin SHI, Jie CHEN, Hui SUN, Hai-wen LI. Effect and Economic Evaluation of the Combination of Traditional Chinese and Western Medicine in Treatment of MDR-TB. Journal of Kunming Medical University, 2020, 41(11): 49-55. doi: 10.12259/j.issn.2095-610X.S20201106
[9]	Xiao-qin LI, Min ZHOU, Lin WANG, Hai-yan ZENG, Peng-ju LUO, Li-jia LIN. Efficacy of PCR-reverse Dot Hybridization in Drug Resistance Gene Detection and Drug Sensitivity of BD960 Tuberculosis in Drug Resistance Tuberculosis Detection. Journal of Kunming Medical University, 2020, 41(12): 138-141. doi: 10.12259/j.issn.2095-610X.S20201238
[10]	Liu Xing , Sun Hui , Du Ying Rong , Chen Jie , Ou Yang Bing , Zhang Le . . Journal of Kunming Medical University, 2020, 41(03): 22-29.
[11]	Shen Ling Jun , Zhu Hui Qiong . . Journal of Kunming Medical University, 2020, 41(02): 100-103.
[12]	Wu Jiang Hai , Shu Jing Kui , Zhang Jian Qing , Feng Jia Gang , Jia Man , Liu Ling . . Journal of Kunming Medical University, 2019, 40(12): 103-107.
[13]	Lv Song Qin , Zhao Hua , Bao Fu Kai , Li Xiao Fei , Yan Xin Li , Zhang Juan , Duan Hong Fen . Combined Application of TNF-α,IFN-γ and T-SPOT.TB in Identification between Active Tuberculosis Infection and Latent Tuberculosis Infection. Journal of Kunming Medical University, 2017, 38(04): 93-97.
[14]	Fan Ping . . Journal of Kunming Medical University,
[15]	Yan Xiao Hua . . Journal of Kunming Medical University,
[16]	Yang Jing . . Journal of Kunming Medical University,
[17]	Shu Jing Kui . . Journal of Kunming Medical University,
[18]	Gao Xiao Jiao . . Journal of Kunming Medical University,
[19]	Wan Rong . . Journal of Kunming Medical University,
[20]	. Investigating Optimal Types of Iatrogenic Bile Duct Injury——A Retrospective Analysis of Clinical Treatment With 52 Cases. Journal of Kunming Medical University,